- Home
- MOV vs DCTH Comparison
MOV vs DCTH Comparison
Compare MOV & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- DCTH
- Stock Information
- Founded
- MOV 1961
- DCTH 1988
- Country
- MOV United States
- DCTH United States
- Employees
- MOV N/A
- DCTH N/A
- Industry
- MOV Consumer Specialties
- DCTH Medical/Dental Instruments
- Sector
- MOV Consumer Discretionary
- DCTH Health Care
- Exchange
- MOV Nasdaq
- DCTH Nasdaq
- Market Cap
- MOV 339.1M
- DCTH 394.9M
- IPO Year
- MOV 1993
- DCTH N/A
- Fundamental
- Price
- MOV $19.26
- DCTH $11.10
- Analyst Decision
- MOV Strong Buy
- DCTH Strong Buy
- Analyst Count
- MOV 1
- DCTH 4
- Target Price
- MOV $31.50
- DCTH $24.50
- AVG Volume (30 Days)
- MOV 154.3K
- DCTH 614.4K
- Earning Date
- MOV 08-28-2025
- DCTH 08-06-2025
- Dividend Yield
- MOV 7.51%
- DCTH N/A
- EPS Growth
- MOV N/A
- DCTH N/A
- EPS
- MOV 0.77
- DCTH 0.06
- Revenue
- MOV $655,597,000.00
- DCTH $70,240,000.00
- Revenue This Year
- MOV $0.71
- DCTH $159.22
- Revenue Next Year
- MOV N/A
- DCTH $41.22
- P/E Ratio
- MOV $24.18
- DCTH $197.50
- Revenue Growth
- MOV 0.79
- DCTH 491.35
- 52 Week Low
- MOV $12.85
- DCTH $8.08
- 52 Week High
- MOV $23.04
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- MOV 76.43
- DCTH 51.36
- Support Level
- MOV $17.88
- DCTH $10.65
- Resistance Level
- MOV $17.55
- DCTH $11.32
- Average True Range (ATR)
- MOV 0.53
- DCTH 0.42
- MACD
- MOV 0.28
- DCTH 0.11
- Stochastic Oscillator
- MOV 99.32
- DCTH 80.62
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.